(Q44512471)

3 December 2017

An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment (English)

1 reference

3 December 2017

0 references

Schey SA

1

1 reference

3 December 2017

Cavenagh J

2

1 reference

3 December 2017

Johnson R

3

1 reference

3 December 2017

Child JA

4

1 reference

3 December 2017

Oakervee H

5

1 reference

3 December 2017

Jones RW

6

1 reference

3 December 2017

language of work or name

1 reference

1 October 2003

1 reference

3 December 2017

1 reference

3 December 2017

27

1 reference

3 December 2017

909-914

1 reference

3 December 2017

10

1 reference

European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Long-term survival in multiple myeloma: a Finnish Leukaemia Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

High-dose glucocorticoid treatment of resistant myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Thalidomide--a revival story

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Analysis of durability of response to thalidomide treatment for relapsed myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

Efficacy of a low dose of thalidomide in advanced multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900027-4

7 January 2021

10.1016/S0145-2126(03)00027-4

Identifiers

DOI

1 reference

3 December 2017

1 reference